[BSX] Boston Scientific: Q3 2026 earnings preview on cyber outage recovery and Watchman

Boston Scientific, a global medical device company that sells single-use cardiovascular, endoscopy and urology devices used in hospital procedures, is scheduled to hold its earnings call on 2026-10-28[1] for the third quarter 2026, the three months ended September 30, 2026. Ahead of this Boston Scientific Q3 2026 earnings report, the latest disclosed quarter is the second quarter of 2026, when net sales were $5.442 billion, up 7.5% on a reported basis and 7.0% organically; GAAP diluted EPS was $0.61 and adjusted EPS was $0.86, compared with $0.75 a year earlier[2], while the adjusted operating margin was 28.4%, up 70 basis points year over year[3]. On July 29 the company guided third-quarter net sales growth of 3% to 5% and adjusted EPS of $0.80 to $0.82, with full-year organic growth of 5% to 6% and adjusted EPS of $3.28 to $3.32[4]; after a cybersecurity incident in late August, it said on September 8 that it was unlikely to meet those ranges and would update its outlook on the third-quarter call[5]. Drillr aggregate data updated on October 16 show a mean third-quarter revenue estimate of $5.099 billion from 15 analysts (range $4.793 billion to $5.326 billion) and a mean EPS estimate of $0.746 (range $0.668 to $0.795)[6]; for the full year, 20 analysts have a mean revenue estimate of $21.190 billion, and 15 analysts have a mean EPS estimate of $3.248 (range $3.178 to $3.308)[7].

Three things matter most in the coming report. First is how large the revenue gap from the cybersecurity incident is and whether it comes back in the fourth quarter: the outage disrupted the company's ability to process and ship orders[5], and with a gross margin of about 69%[8] and fixed costs running through the outage, profit will fall by more than revenue, so the new full-year guidance will show how much the company expects to recapture. Second is whether the Watchman left atrial appendage closure slowdown has bottomed: growth fell from 19% in the first quarter[9] to 4% in the second, and the company guided a mid-to-high single-digit year-over-year decline in global second-half revenue[10], so whether standalone-procedure declines narrow will decide the direction of this high-margin franchise. Third is whether Farapulse pulsed field ablation share losses in the U.S. remain within the July assumptions: U.S. electrophysiology sales were $606 million in the second quarter versus $587 million a year earlier, almost flat[11], and whether international electrophysiology can keep growing at around 20% and offset the U.S. slowdown will determine how the company's largest growth line performs in the second half.

Company Background and Business Structure

Boston Scientific is headquartered in Marlborough, Massachusetts, and its chairman and chief executive officer is Mike Mahoney[12]. At the end of 2025 the company had about 59,000 employees, roughly 60% of them outside the U.S.[13]. It sells to hospitals, clinics, outpatient facilities and medical offices in 127 countries, and large group purchasing organizations, hospital networks and other buying groups account for a substantial portion of net sales; most sales come from countries with direct sales organizations, and each business has dedicated sales forces focused on the relevant physician specialists and hospital service-line administrators[14].

In 2025 the company reported results in two segments, MedSurg and Cardiovascular[13]. Cardiovascular generated $13.250 billion, about 66% of sales, including Interventional Cardiology and Vascular Therapies at $4.639 billion, electrophysiology (EP) at $3.325 billion, Cardiac Rhythm Management at $2.332 billion, Watchman at $1.958 billion and Interventional Oncology and Embolization at $996 million; MedSurg generated $6.824 billion, about 34%, including Endoscopy at $2.916 billion, Urology at $2.709 billion and Neuromodulation at $1.199 billion; by geography, U.S. sales were $12.864 billion, about 64%, and international sales were $7.210 billion[15]. On October 7, 2026, the company named Joe Fitzgerald chief operating officer effective January 1, 2027, and said it will report three segments from that date, Interventional Therapies, Rhythm Solutions and MedSurg, with Rhythm Solutions combining electrophysiology, Watchman and Cardiac Rhythm Management[12].

The business chain runs from manufacturing to hospital reimbursement. Products are designed and made in technology centers around the world by the company or third parties, the manufacturing of any specific product is usually concentrated in one or a few locations, and many products must be sterilized before sale[16]; the company earns revenue mainly from selling single-use medical devices[15], and hospitals then bill third-party payers such as Medicare, Medicaid and private insurers, so access to reimbursement affects which products hospitals buy and what prices they will pay[17]. On the capital side, the company invested $1.5 billion in MiRus during the second quarter for an approximately 34% equity stake and an exclusive option to acquire its transcatheter aortic valve replacement (TAVR) business[18].

Financial History and Current Position

Boston Scientific grew revenue rapidly over the past three years while holding gross margin near 69%. Net sales were $14.240 billion in 2023, $16.747 billion in 2024 and $20.074 billion in 2025, with 2025 growth of 19.9% reported and 15.8% organic[19]. Gross profit was $13.854 billion in 2025, and GAAP gross margin was 69.5%, 68.6% and 69.0% in 2023 through 2025[8]; in 2025, SG&A expenses rose 15% but fell 140 basis points as a share of sales, while R&D expenses rose 27%[20].

Annual cash flow grew alongside revenue and funded acquisitions. Operating cash flow was $2.503 billion, $3.435 billion and $4.534 billion in 2023 through 2025, and in 2025 capital expenditure was $876 million and net acquisition payments were $1.593 billion[21]. At the end of 2025 the company held $1.965 billion of unrestricted cash, had repurchased no shares in 2025 or 2024, and had a $2.750 billion revolving credit facility backing its commercial paper program[22].

Profit kept growing in the first half of 2026, but buybacks and investments absorbed much of the cash. First-half net sales were $10.646 billion, including $5.442 billion in the second quarter; second-quarter GAAP gross profit was $3.848 billion, a 70.7% gross margin compared with 67.7% a year earlier, operating income was $1.178 billion compared with $819 million, and GAAP diluted EPS was $0.61[23]. First-half operating cash flow was $1.822 billion, roughly flat with $1.827 billion a year earlier, inventories rose $310 million, capital expenditure was $372 million, share repurchases were $2.000 billion and commercial paper increased by a net $1.675 billion[24]; that $2 billion accelerated repurchase retired about 40 million shares, and the company also invested $1.5 billion in MiRus[18].

Operating Model

Revenue can be broken down into procedure volume, company share and device value per procedure for each business unit, plus currency and acquisitions. Growth comes from three main sources: new therapies replacing old ones, such as Farapulse replacing thermal ablation, which lifted electrophysiology sales from $1.904 billion in 2024 to $3.325 billion in 2025[15], while the AGENT drug-coated balloon drove coronary therapies[25]; wider indications and referrals, such as Watchman offering patients with non-valvular atrial fibrillation an alternative to oral anticoagulants[26]; and acquisitions. In 2026 the first two sources weakened at the same time in Watchman and U.S. electrophysiology, which together generated $1.423 billion, about 26% of company sales, in the second quarter[11], and changes in procedure volume and share usually reach revenue within the same quarter.

Adjusted operating profit depends on gross margin and the pace of spending, and product mix shifts change the margin directly. In 2025, a higher share of high-margin products added 1.7 percentage points to gross margin, while inventory charges from the ACURATE platform discontinuation, tariffs and other period expenses subtracted 1.3 points[8]. Watchman and electrophysiology carry high margins, so their slowdown creates an unfavorable mix, and the company is also spending more on supply chain and quality systems, which is why it cut its full-year adjusted operating margin expansion guidance to 0 to 25 basis points[10]. The restructuring plan launched in July is expected to cost about $700 million to $800 million before tax and save about $500 million a year[27]; savings appear first in SG&A, with more than half realized by the end of 2027[28], so the margin benefit lags the charges.

Operating cash flow is customer collections minus manufacturing, selling and R&D spending, so lower revenue depresses collections in the same or the following quarter. In the first half of 2026 the company paid for its buyback and the MiRus investment with operating cash flow, cash on hand and new commercial paper[24]. The pending Penumbra deal is valued at about $14.5 billion, of which about $11 billion is to be paid in cash and new debt and the rest in stock[21]; the $6 billion term loan signed in February 2026 can only be drawn at closing and matures 364 days later[29]; and the restructuring plan requires about $600 million to $700 million in cash outlays[27].

Industry and Competitive Position

Boston Scientific leads in both of its most important growth businesses, but those leads are being challenged. Watchman is the leading device in percutaneous left atrial appendage closure globally[26], and Farapulse was the main driver of the company's revenue growth in 2024 and 2025[25]. Management said competitors took share in the fast-growing PFA segment faster than expected, that competitive pressure should last through the first half of 2027, and that Watchman will face a new competitor in 2027[30]. More broadly, the company competes with large manufacturers that have many product lines and with companies focused on a single category, and its 10-K says competition rests mainly on clinical and economic outcomes, ease of use, reliability and physician familiarity[31].

The company is expanding its interventional portfolio through acquisitions, but the available comparison has clear limits. On January 15, 2026, it agreed to buy thrombectomy company Penumbra for $374 per share, or about $14.5 billion[21]; the FTC issued a Second Request on March 16, Penumbra stockholders approved the deal on May 6, and the company expects to close in the second half of the year[29]. The company does not disclose Watchman or electrophysiology procedure volume, share or pricing, and the available disclosures contain no matching competitor data, so share can only be judged through the sequential and year-over-year change in U.S. electrophysiology revenue.

Core Debates

A cybersecurity incident in late August halted Boston Scientific's manufacturing and shipping, and the company has already said it will likely miss its third-quarter and full-year guidance. Can third-quarter results show the loss was confined to the days of the outage and that deferred procedures will return in the fourth quarter rather than going to competitors?

This question matters because the outage directly cut off the supply of single-use devices. The company identified the incident on August 25 and disclosed on August 26 that it had disrupted global operations, including the ability to process and ship customer orders, with no known timeline for full restoration[32]. Its 10-K also warns that manufacturing of a given product is usually concentrated in one or a few locations, that the company may be unable to move production quickly after an interruption, and that it may lose market share it cannot recapture[16]. The third-quarter report is the first financial data since the incident, and the new full-year guidance will tell investors how much the company thinks it can win back.

Current evidence points to a fast recovery, but the size of the loss has not been disclosed. On September 8 the company said its major distribution centers were shipping at or above normal levels, its sterilization facilities were operating and most plants had resumed production; it also concluded the incident was likely to have a material impact on third-quarter and full-year results and said it anticipated recovering some of the affected revenue[5]. As a baseline, second-quarter net sales were $5.442 billion, against $5.203 billion in the first quarter[33], and second-quarter adjusted EPS was $0.86[2]; July guidance called for third-quarter revenue growth of 3% to 5% and adjusted EPS of $0.80 to $0.82[4], while after the incident the 15-analyst mean is $5.099 billion of revenue and $0.746 of EPS[6], already below the level implied by guidance.

The financial path runs from lost revenue to a larger profit decline and then a partial recovery. The outage halted manufacturing, order processing and shipping, so less revenue was recognized in the quarter; with a 69.0% gross margin in 2025[8] and plant and sales-force costs running as usual during the outage, adjusted operating margin and EPS fall more than revenue; once operations recover, deferred procedures and hospital restocking bring some revenue back. The unresolved alternative is that the gap is not only delayed shipments, because some hospitals may have switched to competitors during the outage, which is especially plausible in electrophysiology and Watchman where competition has already intensified, and that revenue would not return in the fourth quarter; the company itself said on September 8 that the full impact was not yet known[5].

The third-quarter report can test this debate in five ways. Investors can check whether third-quarter net sales are at least the $5.099 billion analyst mean, whether the company discloses the revenue impact and the share it expects to recapture in the fourth quarter, whether the midpoint of new full-year adjusted EPS guidance is at least $3.25, whether changes in inventory and receivables show restocking shipments, and whether the investigation finds data exfiltration or added litigation costs. The falsifiers are clear: if third-quarter revenue falls below $4.793 billion[6], the loss exceeds the most pessimistic case the market priced in after the incident; if the midpoint of new full-year adjusted EPS guidance is below $3.18[7], fourth-quarter recapture is limited.

Watchman growth fell from 19% in the first quarter to 4% in the second, and the company expects a year-over-year decline in the second half. Will the third quarter show the drop in standalone-procedure referrals bottoming out, so that growth in concomitant procedures can hold up this high-margin business?

This question matters because Watchman has been one of the company's fastest-growing, higher-margin businesses in recent years. Watchman sales were $1.958 billion in 2025, up about 29% from $1.516 billion in 2024[15]. Procedures come from two sources: standalone closures referred by cardiologists and concomitant closures performed during an atrial fibrillation ablation[3]; in 2026, new clinical studies reduced referrals of patients with softer indications, and the company cut its full-year Watchman growth outlook to flat to low single digits[10].

The latest data show concomitant procedures growing fast but not yet offsetting the standalone decline. Second-quarter Watchman sales were $507 million versus $486 million a year earlier, with $459 million from the U.S. and $48 million internationally[11]; on the company's basis, global growth was 4%, U.S. growth 3% and international growth 18%, and about one-third of U.S. procedures were now concomitant, up more than 60% year over year, while standalone procedures fell by a low-teens percentage[3]. First-quarter Watchman sales were $506 million versus $424 million a year earlier[33], an organic increase of 19%[9]; against company growth of 7.5% in the second quarter[34], Watchman lagged by about 3 percentage points.

The financial effect depends on the net of falling referrals and rising concomitant procedures. New clinical evidence and discussion of guidelines and reimbursement reduced cardiologist referrals for patients with softer indications, cutting standalone procedure volume, while growth in PFA ablation lifted concomitant closures, and together they determine Watchman implants and revenue; a lower share of high-margin products in turn pressures adjusted operating margin. The company still believes CHAMPION-AF data will support an FDA first-line label update and a reconsideration of CMS coverage, with SIMPLAAFY results due in the second half[35], and CHAMPION-AF met all primary and secondary endpoints in April[36]. The alternative view is that the referral decline is not temporary market confusion but a lasting narrowing of indications through clinical guidelines and payer reassessment[17]; if so, concomitant growth can only partly offset it, and the standalone decline will not narrow quickly.

Five indicators in the third quarter can show whether the referral decline has bottomed. Investors can check whether Watchman's year-over-year growth trails company growth by no more than 8 to 13 percentage points, whether the U.S. standalone decline narrows, whether the concomitant share keeps rising, whether international Watchman growth stays above 15%, and how SIMPLAAFY results and the FDA label update progress. The falsifiers are clear: if Watchman trails the company by more than 13 percentage points, the referral decline is deeper than the July view[10]; if international growth drops to single digits, the slowdown is no longer specific to the U.S.

Farapulse drove 75% growth in Boston Scientific's electrophysiology business in 2025, but pulsed field ablation now accounts for roughly 80% of U.S. atrial fibrillation ablation and competitors are taking share, leaving U.S. EP sales almost flat in the second quarter. Will third-quarter U.S. share losses stay within the July guidance, and can international growth keep offsetting them?

This question matters because electrophysiology was the company's largest source of growth in 2024 and 2025. Electrophysiology sales were $3.325 billion in 2025, about 16.6% of company sales and up about 75% from 2024[15]. The Farapulse PFA system treats atrial fibrillation and, together with the OPAL mapping system, anchors the electrophysiology product line[26]; hospitals buy single-use catheters per procedure, so revenue moves with procedure volume and share, and now that PFA has largely replaced thermal ablation in the U.S., growth depends on winning share from competitors, which is why the company cut its second-half global electrophysiology growth guidance to roughly flat[10] and said it expects electrophysiology to rebound in the second half of 2027[37].

Second-quarter data show U.S. electrophysiology close to stalling while international sales keep growing fast. Second-quarter electrophysiology sales were $916 million versus $840 million a year earlier, up about 9%; U.S. sales were $606 million versus $587 million, and international sales were $310 million versus $252 million[11]. First-quarter U.S. electrophysiology sales were $603 million versus $511 million a year earlier, with global electrophysiology at $905 million[33], so U.S. sales were roughly flat sequentially in the second quarter. In its 10-Q the company attributed the sales impact to increased electrophysiology competition[38], and on the call it said PFA now accounts for about 80% of the U.S. atrial fibrillation market and that it had suffered unexpected share losses[3]; its full-year guidance for international electrophysiology growth is about 20%[10].

The financial effect runs from share to margin. Competitor PFA catheter launches and hospital purchasing shifts determine Farapulse's share of U.S. ablation procedures and therefore U.S. electrophysiology catheter and mapping revenue; international PFA penetration drives international electrophysiology revenue, and slower electrophysiology growth creates an unfavorable mix that lowers adjusted operating margin. Management is counting on new catheters for the rebound, and enrollment has begun in the FARAFLEX pivotal trial[37], whose feasibility study showed strong lesion durability[18], while ADVENT long-term results showed higher four-year atrial fibrillation treatment success with Farapulse than with thermal ablation[36]. The alternative view is that part of the U.S. stall reflects slower growth in atrial fibrillation ablation volume itself, not only share; the company does not disclose U.S. procedure volume or share, so a share problem can only be confirmed if U.S. electrophysiology revenue falls again sequentially in the third quarter while management says the market is still growing.

Five measures in the third quarter can show how fast share is being lost. Investors can check whether electrophysiology growth trails company growth by no more than 4 percentage points, whether U.S. electrophysiology sales drop below the second quarter's $606 million, whether international electrophysiology growth stays above 18%, whether management says U.S. share is stabilizing, and how enrollment in the FARAFLEX pivotal trial is progressing. The falsifiers are clear: if electrophysiology trails the company by more than 8 percentage points, share losses are faster than the July view[30]; if international electrophysiology growth falls below 12%, international sales can no longer offset the U.S. slowdown.

Management says the guidance cut came entirely from Watchman and electrophysiology, and that the remaining roughly 75% of the business can still grow about 6% in the second half. Can interventional cardiology and vascular keep leading in the third quarter, can urology stop slipping, and can margins hold up through the cyber disruption?

This question matters because, with Watchman and electrophysiology slowing, future growth and profit depend mainly on the rest of the business and on cost savings. The restructuring plan is expected to deliver about $500 million in annual savings[27], and management said the guidance cut came entirely from Watchman and electrophysiology while the remaining roughly 75% of the business keeps growing at about its historical 6% rate[37]. That portfolio covers coronary and peripheral interventions, endoscopy, urology, neuromodulation and cardiac rhythm management, mostly single-use products used in procedures, and its growth depends on new product uptake and procedure volume.

Second-quarter data show interventional cardiology leading while urology and cardiac rhythm management lag. Second-quarter Interventional Cardiology and Vascular Therapies sales were $1.333 billion versus $1.178 billion a year earlier, up about 13.2% on a reported basis[11]; on the company's basis growth was 12%, with interventional cardiology up 15% on drug-coated balloons, imaging and complex PCI, and the second-quarter adjusted operating margin was 28.4%[3]. MedSurg grew 5.4% organically, with Endoscopy up 7.0%, Neuromodulation up 12.2% and Urology up only 0.8%[34]; Urology grew 0.5% organically in the first quarter[33] and 4.7% for full-year 2025[19]; Cardiac Rhythm Management sales were $585 million in the second quarter, below $590 million a year earlier[11], while GAAP gross margin was 70.7%[23].

The financial question is whether new product uptake can offset lagging businesses and mix pressure. Uptake and procedure volume for new products such as the AGENT drug-coated balloon, coronary imaging, venous therapies and intravascular lithotripsy drive this portfolio's revenue, while the sacral neuromodulation recovery in urology is taking longer than planned[3] and a new cardiac rhythm management platform will not launch until the second half of 2027[37], both weighing on portfolio growth; the unfavorable Watchman and electrophysiology mix and supply-chain and quality spending pressure adjusted operating margin, while restructuring savings reduce SG&A first[28]. The alternative view is that this portfolio's growth is less steady than management says: urology and cardiac rhythm management have lagged for two straight quarters, and part of interventional cardiology's strong growth reflects early-launch effects that may fade over time; at the same time, Penumbra is expected to be slightly dilutive to operating margin and EPS in the near term after closing[30], and the FTC review is still open[29].

Five checks in the third quarter can test whether the rest of the business is holding up. Investors can check whether Interventional Cardiology and Vascular Therapies grows at least 5 percentage points faster than the company, whether urology organic growth recovers above 3%, whether the adjusted operating margin is at least 27.4%, whether management reaffirms roughly 6% growth for this portfolio, and whether Penumbra receives FTC clearance and closes. The falsifiers are clear: if Interventional Cardiology and Vascular Therapies does not grow faster than the company, the portfolio loses its main engine; if the adjusted operating margin falls below 25.9%, margin erosion extends beyond the cyber incident, a threshold derived as a scenario from a revenue loss of about $300 million[39], a 69% gross margin and unchanged expenses, not from company data.

Risks and Falsifiers

Closing and financing Penumbra would change the balance sheet and near-term profit. About $11 billion of the roughly $14.5 billion price is to be paid in cash and new debt[21], the $6 billion term loan can only be drawn at closing, and the FTC Second Request has not concluded[29]; management said the deal will be slightly dilutive to operating margin and EPS in the near term[30], and an FTC challenge would force changes to both the deal timeline and the interventional growth plan. The exposure is total debt, interest expense ($186 million in the first half[23]) and adjusted EPS, and the falsifier is FTC clearance together with company disclosure of post-closing deleveraging and EPS impact.

Hospitals switching to competitors during the outage is the channel most likely to leave lasting damage from the cyber incident. Electrophysiology and Watchman both face rising competition, so if competitors absorbed deferred procedures, the third-quarter gap will not be recaptured in the fourth quarter, and the 10-K itself warns that manufacturing interruptions can cause share losses that may not be recaptured[16]. The exposure is third- and fourth-quarter net sales and adjusted EPS, and at a gross margin of about 69%[8], each $100 million of lost revenue removes about $69 million of gross profit; the falsifier is company disclosure that it expects to recapture more than half of the affected revenue in the fourth quarter[5], together with a new full-year adjusted EPS guidance midpoint of at least $3.25.

A lasting narrowing of Watchman referrals would keep pressure on a high-margin business. New clinical evidence and discussion of guidelines and reimbursement keep reducing referrals of patients with softer indications, and management also expects further share erosion when a new competitor enters in 2027[30]. The exposure is Watchman revenue ($1.958 billion in 2025, about 9.8% of the company[15]) and the mix effect on adjusted operating margin; the falsifier is a standalone-procedure decline narrowing to single digits and the gap between Watchman and company growth returning to within 8 percentage points[10].

Continued U.S. PFA share loss would keep electrophysiology under pressure until new catheters arrive. Competitors may take U.S. PFA share faster than expected, and management does not expect electrophysiology to rebound until the second half of 2027[37]. The exposure is electrophysiology revenue ($3.325 billion in 2025, about 16.6%[15]) and the unfavorable mix from declining electrophysiology and Watchman; the falsifier is U.S. electrophysiology revenue stabilizing sequentially with international electrophysiology growth of at least 18%[11].

A slowdown and margin squeeze in the remaining roughly 75% of the business would mean the guidance cut is no longer confined to two franchises. If urology and cardiac rhythm management keep lagging and interventional cardiology growth slows while the Watchman and electrophysiology mix and supply-chain spending pressure margins, the company loses its main cushion. The exposure is about 74% of revenue and the adjusted operating margin (28.4% in the second quarter[3], with full-year expansion guidance of 0 to 25 basis points[10]); the falsifier is Interventional Cardiology and Vascular Therapies growing at least 5 percentage points faster than the company[34] with an adjusted operating margin of at least 27.4%.

What to Watch Next

• Cyber gap and recapture: third-quarter net sales against $5.442 billion in the second quarter and the $5.099 billion analyst mean, plus any disclosed impact and recapture share; sales below $4.793 billion would mean the loss exceeded the most pessimistic case.
• Cyber gap and recapture: the new full-year adjusted EPS guidance midpoint against the July range of $3.28 to $3.32; at least $3.25 supports recapture, while below $3.18 means recapture is limited.
• Watchman referrals: the gap between Watchman growth (4% in the second quarter) and company growth (7.5%), and whether standalone declines narrow; a gap above 13 percentage points means a deeper decline.
• Watchman referrals: international Watchman growth (18% in the second quarter) staying above 15%; single digits would mean the slowdown is not only a U.S. problem.
• Farapulse share: U.S. electrophysiology sales against $606 million in the second quarter and $603 million in the first, plus management's comments on share; trailing company growth by more than 8 points signals faster share loss.
• Farapulse share: international electrophysiology growth (23% in the second quarter) staying above 18%; below 12% means international can no longer offset the U.S.
• Remaining 75% of the business: Interventional Cardiology and Vascular Therapies growth (about 13.2% reported in the second quarter) at least 5 points above company growth, and urology back above 3%; failing to beat company growth removes the main engine.
• Remaining 75% of the business: adjusted operating margin (28.4% in the second quarter) at or above 27.4%, and Penumbra clearance and closing; below 25.9% signals margin erosion beyond the incident.

Conclusion

Boston Scientific's revenue is driven by procedure volume, physician choice and reimbursement, and over the past three years it expanded quickly on two growth lines, Farapulse and Watchman. Net sales reached $20.074 billion in 2025[19], the adjusted operating margin was 28.4% in the second quarter of 2026[3], and first-half operating cash flow was $1.822 billion[24], so the financial base remains solid. The key unresolved relationship has three layers: how much of the cyber gap is only a timing shift, when the Watchman and U.S. electrophysiology slowdowns bottom out, and whether the remaining roughly 75% of the business can sustain growth and margins.

Two brokers' outside interpretations before the third-quarter report point to different centers of concern. Citi analyst Joanne Wuensch, turning cautious on September 17, argued that the U.S. PFA market is more mature and competitive, that electrophysiology may not improve until new catheters launch in the second half of 2027, and that Citi models Farapulse-related sales falling 5.3% in the second half of 2026 and staying flat in 2027; she also saw the left atrial appendage closure market stagnating with Abbott's Amulet taking share, problems in urology, and cyber effects that could be protracted, saying the time to resolution is opaque and investor patience has run thin[40]. Wells Fargo analyst Larry Biegelsen instead estimated the net impact of eight days of downtime at roughly $300 million in third-quarter sales and about $0.13 per share in earnings, an estimate that assumes no fourth-quarter procedure recapture or inventory build and that the report said could prove conservative[39]. Both see the incident depressing the third quarter, but Citi treats it as a possibly lasting drag layered on structural Watchman and Farapulse problems, in contrast with management's statement that the incident is not expected to have a material impact on its long-term financial condition[5], while Wells Fargo frames it as mainly a 2026 problem and leaves fourth-quarter recapture as the open variable.

A combination of upcoming observations would materially change the picture. If third-quarter revenue is at least the $5.099 billion analyst mean[6], the disclosed recapture share is above half, the new full-year adjusted EPS guidance midpoint is at least $3.25, and at the same time U.S. electrophysiology revenue stabilizes sequentially, the gap between Watchman and company growth narrows and the adjusted operating margin is at least 27.4%, the view that the loss is mainly a timing shift and the slowdown is confined to two businesses would be strengthened. Conversely, if revenue falls below $4.793 billion, the new guidance midpoint is below $3.18, U.S. electrophysiology declines again sequentially, or Interventional Cardiology and Vascular Therapies no longer outgrows the company, the problems are deeper than the July and September assessments suggested.

Sources

[1] Drillr earnings calendar (updated 2026-10-16) · BSX 2026-10-28 call · 2026-10-16 · Drillr earnings calendar

[2] BSX 8-K filed 2026-07-29 · 2Q26 results summary · 2026-07-29 · 8-K · https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000885725&type=8-K&dateb=&owner=include&count=40

[3] BSX Q2 2026 earnings call 2026-07-29 · business unit performance · 2026-07-29 · earnings-call · https://gateway.drillr.ai/mcp/private

[4] BSX 8-K filed 2026-07-29 · full year and third quarter 2026 guidance · 2026-07-29 · 8-K · https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000885725&type=8-K&dateb=&owner=include&count=40

[5] BSX 8-K filed 2026-09-08 · cybersecurity incident restoration and material impact · 2026-09-08 · 8-K · https://www.sec.gov/Archives/edgar/data/0000885725/000088572526000059/bsx-20260907.htm

[6] Drillr analyst_financial_estimates (updated 2026-10-16) · BSX quarter ending 2026-09-30 · 2026-10-16 · Drillr analyst_financial_estimates · https://gateway.drillr.ai/mcp/private

[7] Drillr analyst_financial_estimates (updated 2026-10-16) · BSX FY2026 · 2026-10-16 · Drillr analyst_financial_estimates · https://gateway.drillr.ai/mcp/private

[8] BSX 10-K filed 2026-02-17 · gross profit margin bridge 2023-2025 · 2026-02-17 · 10-K · https://www.sec.gov/Archives/edgar/data/885725/000088572526000010/

[9] BSX Q1 2026 earnings call 2026-04-22 · guidance and Watchman/EP outlook · 2026-04-22 · earnings-call · https://gateway.drillr.ai/mcp/private

[10] BSX Q2 2026 earnings call 2026-07-29 · guidance detail · 2026-07-29 · earnings-call · https://gateway.drillr.ai/mcp/private

[11] BSX 10-Q filed 2026-08-03 · net sales by business unit 2Q26 · 2026-08-03 · 10-Q · https://www.sec.gov/Archives/edgar/data/885725/000088572526000053/bsx-20260630.htm

[12] BSX 8-K filed 2026-10-07 · COO appointment and three reportable segments from 2027 · 2026-10-07 · 8-K · https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000885725&type=8-K&dateb=&owner=include&count=40

[13] BSX 10-K filed 2026-02-17 · reportable segments and employees · 2026-02-17 · 10-K · https://www.sec.gov/Archives/edgar/data/885725/000088572526000010/

[14] BSX 10-K filed 2026-02-17 · marketing and sales channels · 2026-02-17 · 10-K · https://www.sec.gov/Archives/edgar/data/885725/000088572526000010/

[15] BSX 10-K filed 2026-02-17 · net sales by business unit 2023-2025 · 2026-02-17 · 10-K · https://www.sec.gov/Archives/edgar/data/885725/000088572526000010/

[16] BSX 10-K filed 2026-02-17 · manufacturing concentration and sterilization risk · 2026-02-17 · 10-K · https://www.sec.gov/Archives/edgar/data/885725/000088572526000010/

[17] BSX 10-K filed 2026-02-17 · reimbursement and payer dependence · 2026-02-17 · 10-K · https://www.sec.gov/Archives/edgar/data/885725/000088572526000010/

[18] BSX 8-K filed 2026-07-29 · share repurchase, MiRus investment and clinical milestones · 2026-07-29 · 8-K · https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000885725&type=8-K&dateb=&owner=include&count=40

[19] BSX 10-K filed 2026-02-17 · net sales growth by segment 2025 and 2024 · 2026-02-17 · 10-K · https://www.sec.gov/Archives/edgar/data/885725/000088572526000010/

[20] BSX 10-K filed 2026-02-17 · SG&A and R&D expenses 2025 · 2026-02-17 · 10-K · https://www.sec.gov/Archives/edgar/data/885725/000088572526000010/

[21] BSX 10-K filed 2026-02-17 · cash flows 2023-2025 and Penumbra agreement · 2026-02-17 · 10-K · https://www.sec.gov/Archives/edgar/data/885725/000088572526000010/

[22] BSX 10-K filed 2026-02-17 · cash and credit facility · 2026-02-17 · 10-K · https://www.sec.gov/Archives/edgar/data/885725/000088572526000010/

[23] BSX 10-Q filed 2026-08-03 · consolidated statements of operations 2Q26 · 2026-08-03 · 10-Q · https://www.sec.gov/Archives/edgar/data/885725/000088572526000053/bsx-20260630.htm

[24] BSX 10-Q filed 2026-08-03 · cash flows 1H26 · 2026-08-03 · 10-Q · https://www.sec.gov/Archives/edgar/data/885725/000088572526000053/bsx-20260630.htm

[25] BSX 10-K filed 2026-02-17 · Cardiovascular growth drivers 2025 · 2026-02-17 · 10-K · https://www.sec.gov/Archives/edgar/data/885725/000088572526000010/

[26] BSX 10-K filed 2026-02-17 · Watchman and Electrophysiology products · 2026-02-17 · 10-K · https://www.sec.gov/Archives/edgar/data/885725/000088572526000010/

[27] BSX 8-K filed 2026-07-27 · 2026 restructuring plan · 2026-07-27 · 8-K · https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000885725&type=8-K&dateb=&owner=include&count=40

[28] BSX Q2 2026 earnings call 2026-07-29 · restructuring Q&A · 2026-07-29 · earnings-call · https://gateway.drillr.ai/mcp/private

[29] BSX 10-Q filed 2026-08-03 · Penumbra status and acquisition financing · 2026-08-03 · 10-Q · https://www.sec.gov/Archives/edgar/data/885725/000088572526000053/bsx-20260630.htm

[30] BSX Q2 2026 earnings call 2026-07-29 · stated risks · 2026-07-29 · earnings-call · https://gateway.drillr.ai/mcp/private

[31] BSX 10-K filed 2026-02-17 · competition · 2026-02-17 · 10-K · https://www.sec.gov/Archives/edgar/data/885725/000088572526000010/

[32] BSX 8-K filed 2026-08-26 · cybersecurity incident disclosure · 2026-08-26 · 8-K · https://www.sec.gov/Archives/edgar/data/0000885725/000088572526000056/bsx-20260826.htm

[33] BSX 10-Q filed 2026-05-01 · net sales by segment and business unit 1Q26 · 2026-05-01 · 10-Q · https://www.sec.gov/Archives/edgar/data/885725/000088572526000033/

[34] BSX 10-Q filed 2026-08-03 · net sales by segment 2Q26 · 2026-08-03 · 10-Q · https://www.sec.gov/Archives/edgar/data/885725/000088572526000053/bsx-20260630.htm

[35] BSX Q2 2026 earnings call 2026-07-29 · Watchman Q&A · 2026-07-29 · earnings-call · https://gateway.drillr.ai/mcp/private

[36] BSX 8-K filed 2026-04-22 · 1Q26 clinical results CHAMPION-AF and ADVENT · 2026-04-22 · 8-K · https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000885725&type=8-K&dateb=&owner=include&count=40

[37] BSX Q2 2026 earnings call 2026-07-29 · EP and 2027 framework Q&A · 2026-07-29 · earnings-call · https://gateway.drillr.ai/mcp/private

[38] BSX 10-Q filed 2026-08-03 · Cardiovascular drivers 2Q26 · 2026-08-03 · 10-Q · https://www.sec.gov/Archives/edgar/data/885725/000088572526000053/bsx-20260630.htm

[39] Yahoo Finance 2026-09-28 · Could Boston Scientific's $300 Million Cyber Hit Be Mostly a 2026 Problem? · 2026-09-28 · Yahoo Finance(转载 Insider Monkey,报道 Wells Fargo 研究观点) · https://finance.yahoo.com/healthcare/articles/could-boston-scientific-300-million-185642181.html

[40] Investing.com 2026-09-17 · Citi downgrades Boston Scientific on uncertain recovery path · 2026-09-17 · Investing.com(报道 Citi 研究观点) · https://www.investing.com/news/stock-market-news/citi-downgrades-boston-scientific-on-uncertain-recovery-path-4905360